Stakeholders Guess At Part B Drug Policies That CMS Might Test

Since CMS let slip Feb. 5 that it is considering a Part B drug reimbursement demonstration , lobbyists and consultants are reviewing potential policies that the agency might test, including options from last year’s report by the Medicare Payment Advisory Commission (MedPAC). Although CMS revealed few details about the possible demonstration, consultants say it is clear the agency is serious about using its administrative power to test whether new approaches to physician reimbursement would encourage physicians to prescribe cheaper drugs...